Glenmark Pharmaceuticals is currently trading at Rs. 541.00, up by 3.85 points or 0.72% from its previous closing of Rs. 537.15 on the BSE.
The scrip opened at Rs. 542.50 and has touched a high and low of Rs. 554.65 and Rs. 538.25 respectively. So far 23743 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 612.00 on 12-Jul-2013 and a 52 week low of Rs. 386.50 on 05-Oct-2012.
Last one week high and low of the scrip stood at Rs. 554.65 and Rs. 500.05 respectively. The current market cap of the company is Rs. 14756.24 crore.
The promoters holding in the company stood at 48.30% while Institutions and Non-Institutions held 40.97% and 10.73% respectively.
Glenmark Pharmaceuticals is in talks with some leading local and global drug makers, for the sale of its oral contraceptive product division, which manufactures generic anti-pregnancy medicine. The company has almost the entire range of about 19 variants of the oral contraceptive, which includes its existing product line and ANDAs pending approvals. The niche hormonal product is manufactured at the company's factory in Goa and has a market size of more than $2.5 billion in the US.
With few players managing to enter this segment due to its complex manufacturing technology, the product is a high-margin product. Further, Glenmark is the third company after Israel's Teva and American Actavis Inc with the capability of manufacturing this product.
Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1788.15 |
Dr. Reddys Lab | 1355.50 |
Cipla | 1469.95 |
Lupin | 2191.35 |
Zydus Lifesciences | 1004.00 |
View more.. |